Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Purpose: Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic and pharmacodynamic study of two formulations of pazopanib was performed in children with STS or other refractory solid tumors. Patients and Methods: Pazopanib (tablet formulation) was administered once daily in 28-day cycles at four dose levels (275 to 600 mg/m 2 ) using the rolling-six design. Dose determination for a powder suspension was initiated at 50% of the maximum-tolerated dose (MTD) for the intact tablet. Ten patients with STS underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) scanning at baseline and 15 ± 2 days after initiation of pazopanib at the tablet MTD. Results: Fifty-three patients were enrolled; 51 were eligible (26 males; median age, 12.9 years; range, 3.8 to 23.9 years). Hematologic and nonhematologic toxicities were generally mild, with dose-limiting lipase, amylase, and ALT elevation, proteinuria, and hypertension. One patient with occult brain metastasis had grade 4 intracranial hemorrhage. The MTD was 450 mg/m 2 for tablet and 160 mg/m 2 for suspension. Steady-state trough concentrations were reached by day 15 and did not seem to be dose dependent. One patient each with hepatoblastoma or desmoplastic small round cell tumor achieved a partial response; eight patients had stable disease for ≥ six cycles, seven of whom had sarcoma. All patients with evaluable DCE-MRI (n = 8) experienced decreases in tumor blood volume and permeability (P < .01). Placental growth factor increased, whereas endoglin and soluble vascular endothelial growth factor receptor-2 decreased (P < .01; n = 41). Conclusion: Pazopanib is well tolerated in children, with evidence of antiangiogenic effect and potential clinical benefit in pediatric sarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Gerber, H.-P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,085
Sleijfer, S., Ray-Coquard, I., Papai, Z., Le Cesne, A., Scurr, M., Schöffski, P., Collin, F., Pandite, L., Marreaud, S., De Brauwer, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3223 · Cited by 679
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., Figlin, R. A., Baum, M. S., & Motzer, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr128 · Cited by 579
Kumar, R., Knick, V. B., Rudolph, S. K., Johnson, J. H., Crosby, R. M., Crouthamel, M.-C., Hopper, T. M., Miller, C. G., Harrington, L. E., Onori, J. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0193 · Cited by 517 · cited 2×
“g/mL (40 mol/L).(1) On the basis of its protein binding of 99.”
BackgroundResting and activated endothelial cells are increased in the peripheral blood of cancer patients
Mancuso, P., Burlini, A., Pruneri, G., Goldhirsch, A., Martinelli, G., & Bertolini, F. (2001) · Blood · doi:10.1182/blood.v97.11.3658 · Cited by 421 · cited 1×
“Cells were immediately analyzed using previously described four-color flow cytometry methods.(12,13) cDNA preparation was carried out using First Strand cDNA Synthesis Kits for RT-PCR (Roche Diagnostics, Indianapolis, IN) and Superscript II (Invitrogen, Carlsbad, CA).”
MethodPhase I Trial of Pazopanib in Patients with Advanced Cancer
Hurwitz, H. I., Dowlati, A., Saini, S., Savage, S., Suttle, A. B., Gibson, D. M., Hodge, J. P., Merkle, E. M., & Pandite, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2740 · Cited by 418 · cited 2×
“1 g/mL hr, respectively, for adults treated at the equivalent dose.(15) Doseproportional increases in AUC and Css were not demonstrated, which may be a result of the wide age range of children enrolled onto this study, the large variability in oral clearance for children 12 years old, the effect of food on absorption,…”
BackgroundScartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., & Cascinu, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn637 · Cited by 327
Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
Skolnik, J. M., Barrett, J. S., Jayaraman, B., Patel, D., & Adamson, P. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7712 · Cited by 282 · cited 1×
“Cycle 1 toxicities were used for the purpose of dose escalations according to the rolling-six design.(10) Patients who developed a DLT or received at least 85% of the prescribed dose during cycle 1 were considered fully evaluable for toxicity.”
MethodBender, J. L. G., Adamson, P. C., Reid, J. M., Xu, L., Baruchel, S., Shaked, Y., Kerbel, R. S., Cooney-Qualter, E. M., Stempak, D., Chen, H. X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9230 · Cited by 249 · cited 2×
“Cells were immediately analyzed using previously described four-color flow cytometry methods.(12,13) cDNA preparation was carried out using First Strand cDNA Synthesis Kits for RT-PCR (Roche Diagnostics, Indianapolis, IN) and Superscript II (Invitrogen, Carlsbad, CA).”
BackgroundMethodSelf-citationHahn, O. M., Yang, C., Medved, M., Karczmar, G., Kistner, E., Karrison, T., Manchen, E., Mitchell, M., Ratain, M. J., & Stadler, W. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5655 · Cited by 230 · cited 1×
“Vascular and permeability changes on DCE-MRI have gained acceptance as pharmacodynamic markers, but their value as predictors of clinical outcome have not been established.(23,24) To our knowledge, this is thefirstpediatric,multicentertrial tosystematicallyevaluateDCE-MRIin STS, demonstrating the feasibility of perfor…”
BackgroundBroniscer, A., Baker, J. N., Tagen, M., Onar‐Thomas, A., Gilbertson, R. J., Davidoff, A. M., Panandiker, A. S. P., Leung, W. H., Chin, T. K., Stewart, C. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3545 · Cited by 126
Nikolinakos, P. G., Altorki, N. K., Yankelevitz, D. F., Tran, H. T., Yan, S., Rajagopalan, D., Bordogna, W., Ottesen, L. H., & Heymach, J. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2533 · Cited by 121 · cited 1×
“Similarly, pazopanib-treated adults with non–small-cell lung cancer showed decreases in sVEGFR-2 and increases in PlGF, and it was suggested that post-treatment changes in plasma sVEGFR-2 could be significantly correlated with tumor shrinkage.(22) In our study, degree of change in sVEGFR-2 was associated with Css but…”
BackgroundFox, E., Aplenc, R., Bagatell, R., Chuk, M. K., Dombi, E., Goodspeed, W. J., Goodwin, A., Kromplewski, M., Jayaprakash, N., Marotti, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9674 · Cited by 113
DuBois, S. G., Shusterman, S., Ingle, A. M., Ahern, C. H., Reid, J. M., Wu, B., Baruchel, S., Glade-Bender, J., Ivy, P., Grier, H. E., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0237 · Cited by 112
Self-citationHeath, E. I., Chiorean, E. G., Sweeney, C. J., Hodge, J. P., Lager, J. J., Forman, K., Malburg, L., Arumugham, T., Dar, M. M., Suttle, A. B., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.199 · Cited by 106
George, S., Reichardt, P., Lechner, T., Li, S., Cohen, D. P., & Demetri, G. D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds179 · Cited by 86
Kumar, S., Mokhtari, R. B., Sheikh, R., Wu, B. H., Zhang, L., Xu, P., Man, S., Oliveira, I. D., Yeger, H., Kerbel, R. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0078 · Cited by 83
Self-citationDemšar, F., Roberts, T. P. L., Schwickert, H. C., et al. (1997) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910370216 · Cited by 82 · cited 1×
“DCE-MRI DCE-MRI scans were performed on non-necrotic target lesions ( 2 cm and not sensitive to motion artifact) at baseline and day 15 2, coincident with PK trough sampling, using previously published methods.(14) DCE-MRI data sets were centrally reviewed and analyzed using a two-compartment kinetic model yielding es…”
MethodSelf-citationHeath, E. I., Forman, K., Malburg, L., Gainer, S. D., Suttle, A. B., Adams, L. M., Ball, H., & LoRusso, P. M. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9725-2 · Cited by 46 · cited 2×
“Adults receiving suspension demonstrated exposures of approximately 133% that of tablet.(7) Similarly, pazopanib bioavailability in children seemed to be higher with the suspension, but the difference was not statistically significant, most likely because of the limited data and broad range in AUC values among patient…”
BackgroundKeir, S. T., Morton, C. L., Wu, J., Kurmasheva, R. T., Houghton, P. J., & Smith, M. A. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24016 · Cited by 39
Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors
Bender, J. G., Yamashiro, D. J., & Fox, E. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0148 · Cited by 25 · cited 1×
“Although the majority of these studies have shown no change, they have been limited by the short duration of therapy typically administered on phase I trials.(28) This finding highlights that ongoing growth plate monitoring remains warranted in patients who have not attained adult height.”
BackgroundBender, J. G., Blaney, S. M., Borinstein, S. C., Reid, J. M., Baruchel, S., Ahern, C. H., Ingle, A. M., Yamashiro, D. J., Chen, A. P., Weigel, B. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0078 · Cited by 22
Self-citation
Cited by
Ségaliny, A. I., Tellez-Gabriel, M., Heymann, M.-F., & Heymann, D. (2015) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.01.001 · Cited by 164
Metadata
- Authors
- Glade Bender, J. L., Lee, A., Reid, J. M., Baruchel, S., Roberts, T., Voss, S. D., Wu, B., Ahern, C. H., Ingle, A. M., Harris, P., Weigel, B. J., & Blaney, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-08-20
- Volume
- 31
- Issue
- 24
- Pages
- 3034-3043
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1976382591
- Cited by
- 167
- References
- 26
- FWCI
- 12.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.